Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

Insights into treating higher-risk MDS: looking forward to 2027

Yazan Madanat, MD, UT Southwestern Medical Center, Dallas, TX, outlines his plan to treat higher-risk myelodysplastic syndromes (MDS) in 2027. Dr Madanat highlights why recent doublet trials have failed, the emerging role of oral hypomethylating agents, novel BCL-2 inhibitors, intensive chemotherapy, and IDH1 inhibition, and a treatment algorithm guided by genetic subtype, blast percentage, and transplant candidacy. This presentation took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, DC.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.